Elon Musk wants to merge humans with AI. And his goal of achieving “symbiosis” with artificial intelligence starts with a brain chip.

A DGIST research team, led by Professor Kyung-In Jang, has developed a smart patch capable of real-time biometric signal monitoring and drug delivery. This patch integrates various sensors and a drug delivery system into a single unit using a foldable structure, enabling real-time cardiovascular health monitoring and immediate drug administration when necessary. The research team expects this technology to be widely applicable across multiple medical fields, including glucose management, pain relief, and chronic disease treatment.

RapidAI announced that it received FDA 510(k) clearance for its Lumina 3D automated 3D imaging reconstruction solution.

Technology is available to assist with nearly every facet of modern life, including helping to prevent people with dementia from wandering and alerting their caregivers when they do.

A research group from the Institute for Research on Next-generation Semiconductor and Sensing Science (IRES²) at Toyohashi University of Technology has developed an innovative in vivo electrophysiological neural recording technology that minimizes neuronal death and allows stable recordings for over a year.

A team of biomolecular engineers, pathologists, and internal medicine specialists at the University of Texas Medical Branch, working with a colleague from the University of Houston, has developed a quick test for tick-borne spotted fever rickettsioses (SFRs).

INDIANAPOLIS, Jan. 29, 2025 /PRNewswire/ — Roche announced today that the Tina-quant® Lipoprotein (a) Gen.2 Molarity assay has received 510(k) clearance from the United States Food and Drug Administration (FDA). This will be the first 510(k) cleared test of its kind available in the U.S. measuring lipoprotein (a), or Lp(a), in nanomoles per liter (nmol/L). The National Lipid Association (NLA) recommends all adults measure their Lp(a) – often referred to as L-P-Little-A – at least once in a lifetime to help assess cardiovascular risk.

RICHMOND, Va. and ATLANTA, Jan. 29, 2025 /PRNewswire/ — OrthoPreserve, a company developing orthopedic implant solutions, announced today it has been granted both a Breakthrough Device Designation and Total Product Life Cycle Advisory Program (TAP) enrollment from the U.S. Food & Drug Administration (FDA) for Defender, a meniscus replacement implant.